Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115088
Chunk: 48

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 48
---
 results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; |

| • |     | the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; |

| • |     | the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; |

| • |     | the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; |

| • |     | our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; |

| • |     | the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, is adopted by the physician community; |

| • |     | our need to expand our research and development activities; |

| • |     | the costs of acquiring, licensing or investing in businesses, product candidates and technologies; |

| • |     | the effect of competing products and product candidates and other market developments; |

| • |     | the number and types of future products we develop and commercialize; |

| • |     | any product liability or other lawsuits related to our products; |

| • |     | the expenses needed to attract, hire and retain skilled personnel; |

| • |     | the costs associated with being a public company; |

| • |     | our need to implement additional internal systems and infrastructure, including financial and reporting systems; |

| • |     | the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; |

| • |     | the costs related to servicing of our debt; |

| • |     | the costs of financing additional clinical, regulatory and commercial activities; and |

| • |     | the extent and scope of our general and administrative expenses. |

**Until we are able to generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic 29

transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. Any additional fundraising efforts may divert our management from